The Canadian government has agreed to provide up to $175.6m to support AbCellera in the development of antibody-based therapies against Covid-19.
In addition, the funds will be used to develop technology and manufacturing infrastructure for antibody therapies for future pandemics.
AbCellera is using its antibody discovery platform to analyse blood samples of people who have recovered from Covid-19 to potentially discover antibodies that could treat and prevent the infection.
Since 25 February, the company could identify more than 500 unique human anti-SARS-CoV-2 antibodies in alliance with the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases in the US.